248
Participants
Start Date
May 31, 2006
Primary Completion Date
September 30, 2012
Study Completion Date
April 30, 2014
Ipilimumab
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Local Institution, Brussels
Local Institution, Vienna
Local Institution, Brussels
Local Institution, Brussels
Local Institution, Johannesburg
Local Institution, Cape Town
Local Institution, Aarhus C
Memorial Sloan Kettering Cancer Center, New York
Local Institution, Genova
Local Institution, Jaú
Carolinas Medical Center, Charlotte
Local Institution, Málaga
Local Institution, Brest
Cancer Centers Of The Carolinas, Greenville
Baptist Cancer Institute, Jacksonville
The Christ Hospital Cancer Center Research, Cincinnati
Local Institution, Valencia
Indiana Oncology Hematology Consultants, Indianapolis
Local Institution, Meldola (Fc)
Local Institution, Rimini
Local Institution, Dnipro
Local Institution, Siena
Local Institution, Vandœuvre-lès-Nancy
University Of Chicago, Chicago
Washington University School Of Medicine, St Louis
Local Institution, Tel Aviv
St Joseph Oncology Inc, Saint Joseph
Local Institution, Heidelberg
Local Institution, Lyon
Local Institution, Paris
Center For Oncology Research & Treatment, P.A., Dallas
Joe Arrington Cancer Research And Treatment Center, Lubbock
University Of Arizona Cancer Center, Tucson
The Angeles Clinic & Research Inst., Los Angeles
Usc/Norris Comprehensive Cancer Center, Los Angeles
Local Institution, Porto Alegre
Local Institution, Lodz
Local Institution, Porto Alegre
Local Institution, Jerusalem
Wilshire Oncology Medical Group Inc, Laverne
San Francisco Oncology Associates, San Francisco
Providence Portland Medical Center, Portland
University Of Washington Medical Center, Seattle
Local Institution, Saint Petersburg
Local Institution, Stavropol
Local Institution, Voronezh
Local Institution, To Come
Local Institution, Buenos Aires
Local Institution, Wels
Local Institution, Calgary
Local Institution, Edmonton
Local Institution, Moncton
Local Institution, Olomouc
Local Institution, Berlin
Local Institution, Kiel
Local Institution, Oslo
Local Institution, Poznan
Local Institution, Wroclaw
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY